Inclusion Criteria:

          -  Signed Informed Consent Form

          -  Age≥18 years

          -  Histologically or cytologically documented(include both dose escalation stage and dose
             expansion stage), incurable, locally advanced, or metastatic solid malignancy

          -  In the dose escalation stage: patients with any malignant solid tumor type for whom
             standard therapy either has proven to be ineffective (progressed on, or failed to
             respond to) or intolerable, have no access to standard systemic therapy or standard
             systemic therapy does not exist.

          -  In the dose expansion stage:

        Metastatic or locally advanced gastric cancer patients with cMet positive b)Metastatic or
        locally advanced EGFR wild type NSCLC patients and with cMet positive.

          -  ECOG performance status of 0, or 1

          -  Male or female patients of child-producing potential must agree to use double barrier
             contraception, condoms, sponge, foams, jellies, diaphragm or intrauterine device
             (IUD), contraceptives (oral or parenteral), Implanon, injectables or other avoidance
             of pregnancy measures during the study and for 90 days after the last day of treatment

        Exclusion Criteria:

          -  Absolute neutrophil count <1500 cells/uL, hemoglobin <9 g/dL or platelet count <
             100,000/mm3

          -  Total bilirubin > 1.5×the the upper limit of normal(ULN).

          -  Herbal therapy <1 week prior to Day 1

          -  Adverse events from prior anti-cancer therapy that have not resolved to Grade ≤ 1,
             except for alopecia

          -  Clinical significant active infection

          -  Known clinically significant history of liver disease, including viral or other
             hepatitis, current alcohol abuse, or cirrhosis

          -  Known human immunodeficiency virus infection

          -  Pregnant (positive pregnancy test) or lactating women

          -  Inability to take oral medication, prior surgical procedures affecting absorption, or
             active peptic ulcer disease

          -  Involved in other clinical trials < 4weeks prior to Day 1.